Tredence today announced at Snowflake's annual user conference, Snowflake Summit 2025, that it has been named the 2025 Retail ...

Oppenheimer maintained its Outperform rating on Trevi Therapeutics, Inc. (NASDAQ: TRVI) shares and lifted the price target ...

Oppenheimer increased its price target for Trevi Therapeutics Inc. (NASDAQ:TRVI) to $23 from $20, while maintaining an ...

Trevi Therapeutics reported a smaller-than-expected loss per share for Q1 2025, with an EPS of -$0.09 compared to the forecasted -$0.13. According to InvestingPro data, two analysts have recently ...

topline results continue to be expected in the second quarter of 2025 Announced positive topline results from the Phase 2a RIVER trial in patients with refractory chronic cough Trevi Therapeutics ...

Trevi Therapeutics TRVI is preparing to release its quarterly earnings on Thursday, 2025-05-08. Here's a brief overview of what investors should keep in mind before the announcement. Analysts ...

Trevi Therapeutics has a 52-week low of $2.30 and a 52-week high of $7.39. The company has a market capitalization of $537.55 million, a PE ratio of -12.64 and a beta of 0.41.

NEW HAVEN, Conn., April 3, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI ), a clinical-stage biopharmaceutical company developing the investigational therapy HaduvioTM (oral ...

B. Riley restated their buy rating on shares of Trevi Therapeutics (NASDAQ:TRVI – Free Report) in a research note issued to investors on Wednesday morning,Benzinga reports. B. Riley currently ...

Fintel reports that on March 10, 2025, Raymond James upgraded their outlook for Trevi Therapeutics (NasdaqGM:TRVI) from ...

Dec. 16, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (TRVI), a clinical ... Frazier Life Sciences, Logos Capital, MPM BioImpact, Rubric Capital Management LP and Vivo Capital.